The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche; Sanofi; SERVIER; Takeda
Speakers' Bureau - AstraZeneca; Janssen; Merck; Mirati Therapeutics
Other Relationship - Genomica
A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets).
 
Anne-Marie C. Dingemans
Honoraria - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Speakers' Bureau - Janssen (Inst)
Research Funding - Amgen (Inst)
 
Frank Griesinger
Employment - Pius Hospital Oldenburg
Leadership - Director Clinic for Hematology and Oncology
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - Abbvie; AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche; Sanofi; Takeda
Research Funding - CRISP study
Expert Testimony - Abbvie; AstraZeneca; Boehringer Ingelheim; MSD; Pfizer; Roche; Sanofi; Takeda
 
Luis Paz-Ares
No Relationships to Disclose
 
Maurice Perol
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daïchi Sankyo; GlaxoSmithKline; Gritstone Bio; Janssen Oncology; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck Sharp & Dohme; Pfizer; Roche; Takeda
 
Shengxiang Ren
No Relationships to Disclose
 
Elen Höglander
Employment - Roche
Stock and Other Ownership Interests - Nykode Therapeutics
 
Nino Kurtsikidze
Employment - Roche Pharma AG
Stock and Other Ownership Interests - Roche Pharma AG
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche